Republic of Korea Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2015

Global Markets Direct, June 2009, Pages: 99

Republic of Korea Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2015

Summary

This report is an essential source for in-depth information and data relating to Republic of Korea diabetes care devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the diabetes care devices market in Republic of Korea

Scope

- The report provides diabetes care devices information broken down into detailed categories and segments in Republic of korea.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.

Reasons to buy

- Gain a strong understanding of the diabetes care devices market in Republic of Korea.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets Covered in the Report
3.1 Diabetes Care Devices
3.2 Glucose Monitoring Devices
3.2.1 Blood Glucose Meters
3.2.2 Blood Glucose Strips
3.3 Insulin Delivery
3.3.1 Insulin Pens
3.3.2 Insulin Syringes
3.3.3 Insulin Pumps
3.3.4 Traditional Insulin Pump Accessories
4 Healthcare Sector Review
4.1 Healthcare Expenditure
4.2 Healthcare Infrastructure
4.3 Healthcare Policy
5 Regulation System
5.1 Medical Equipment Approval Process
5.1.1 Classification
5.1.2 Premarket Notification for Class I Devices
5.1.3 Pre-market Approval for Class II, III and IV Devices
5.1.4 License Fee
5.1.5 License Application Processing Duration
5.2 Post-market Surveillance
6 Pricing and Reimbursement
7 Distribution Structure
7.1 Distribution Structure
8 Diabetes Care Devices In Republic of Korea
8.1 Diabetes Care Devices, Cross Country Comparison, Revenue ($ mn), 2000-2015
8.2 Diabetes Care Devices, Republic of Korea, Overall Revenue ($ mn), 2000-2015
8.3 Diabetes Care Devices, Republic of Korea, Category Volume (Units), 2000-2015
8.4 Diabetes Care Devices, Republic of Korea, Company Share (2007-2008)
9 Glucose Monitoring In Republic of Korea
9.1 Glucose Monitoring Overall Revenue (2000-2015)
9.2 Glucose Monitoring Overall Volume (2000-2015)
9.3 Glucose Monitoring Average Price (2000-2015)
9.4 Glucose Monitoring Distribution Share (2007-2008)
9.5 Glucose Monitoring, Republic of Korea, Company Share (2007-2008)
10 Insulin Delivery In Republic of Korea
10.1 Insulin Delivery Overall Revenue (2000-2015)
10.1.1 Insulin Pens Revenue (2000-2015)
10.2 Insulin Delivery Overall Volume (2000-2015)
10.2.1 Insulin Pens Volume (2000-2015)
10.3 Insulin Delivery Average Price (2000-2015)
10.4 Insulin Delivery Distribution Share (2007-2008)
10.5 Insulin Delivery, Republic of Korea, Company Share (2007-2008)
11 Overview of Key Companies in Republic of Korea Diabetes Care Devices Market
11.1 Terumo Corporation
11.1.1 Company Overview
11.1.2 Value Chain Analysis
11.2 Smiths Medical
11.2.1 Company Overview
11.2.2 Value Chain Analysis
11.3 Sanofi-Aventis
11.3.1 Company Overview
11.4 Novo Nordisk A/S
11.4.1 Company Overview
11.4.2 Novo Nordisk A/S Pipeline Products
11.5 Medtronic, Inc.
11.5.1 Company Overview
11.5.2 Value Chain Analysis
11.5.3 Medtronic, Inc. Pipeline Products
11.6 LifeScan, Inc.
11.6.1 Company Overview
11.6.2 LifeScan, Inc. Pipeline Products
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 Company Overview
11.7.2 Value Chain Analysis
11.7.3 F. Hoffmann-La Roche Ltd Pipeline Products
11.8 Eli Lilly and Company
11.8.1 Company Overview
11.8.2 Value Chain Analysis
11.8.3 Eli Lilly and Company Pipeline Products
11.9 Becton, Dickinson and Company
11.9.1 Company Overview
11.9.2 Value Chain Analysis
11.10 Bayer HealthCare AG
11.10.1 Company Overview
11.10.2 Value Chain Analysis
11.10.3 Bayer HealthCare AG Pipeline Products
11.11 ARKRAY, Inc.
11.11.1 Company Overview
11.11.2 ARKRAY, Inc. Pipeline Products
11.12 Apex Biotechnology Corp.
11.12.1 Company Overview
11.13 Animas Corporation
11.13.1 Company Overview
11.14 Abbott Laboratories
11.14.1 Company Overview
11.14.2 Value Chain Analysis
11.14.3 Abbott Laboratories Pipeline Products
11.15 Shina Corporation
11.15.1 Company Overview
12 Appendix
12.1 Global Markets Direct Research Methodology
12.2 Coverage
12.3 Secondary Research
12.4 Primary Research
12.5 Models
12.6 Forecasts
12.7 Expert Panel Validation
12.8 Currency Conversion
12.9 Contact Us
12.10 Disclaimer

Executive Summary

1.1 List of Tables
Table 1: Hospital Wards by Specialty in Republic of Korea, 2003-2007 16
Table 2: Doctors by Specialty in Republic of Korea, 2003-2007 17
Table 3: Healthcare Institutions in Republic of Korea, 2001-2005 18
Table 4: Healthcare Personnel in Republic of Korea, 1975-2002 18
Table 5: Classification of Medical Equipment in Republic of Korea 20
Table 6: Diabetes Care Devices, Cross Country Comparison, Revenue ($ mn), 2000-2015 28
Table 7: Diabetes Care Devices, Republic of Korea, Overall Revenue ($ mn), 2000-2015 29
Table 8: Diabetes Care Devices, Republic of Korea, Cross-Category Analysis, 2000-2015 30
Table 9: Diabetes Care Devices, Republic of Korea, Overall Revenue ($ mn), Historic, 2000-2008 31
Table 10: Diabetes Care Devices, Republic of Korea, Overall Revenue ($ mn), Forecast, 2008-2015 32
Table 11: Diabetes Care Devices, Republic of Korea, Category Volume (Units), 2000-2015 33
Table 12: Diabetes Care Devices, Republic of Korea, Category Volume (Units), Historic, 2000-2008 34
Table 13: Diabetes Care Devices, Republic of Korea, Category Volume (Units), Forecast, 2008-2015 35
Table 14: Diabetes Care Devices, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 36
Table 15: Glucose Monitoring, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 37
Table 16: Glucose Monitoring, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 38
Table 17: Glucose Monitoring, Republic of Korea, Volume (Units) by Segment, Historic, 2000-2008 39
Table 18: Glucose Monitoring, Republic of Korea, Volume (Units) by Segment, Forecast, 2008-2015 40
Table 19: Glucose Monitoring, Republic of Korea, Average Price ($), Historic, 2000-2008 41
Table 20: Glucose Monitoring, Republic of Korea, Average Price ($), Forecast,, 2008-2015 41
Table 21: Glucose Monitoring, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 41
Table 22: Glucose Monitoring, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 42
Table 23: Insulin Delivery, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 43
Table 24: Insulin Delivery, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 44
Table 25: Insulin Pens, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 45
Table 26: Insulin Pens, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 46
Table 27: Insulin Delivery, Republic of Korea, Volume (Units) by Segment, Historic, 2000-2008 47
Table 28: Insulin Delivery, Republic of Korea, Volume (Units) by Segment, Forecast, 2008-2015 47
Table 29: Insulin Pens, Republic of Korea, Volume (Units) by Sub-Segment, Historic, 2000-2008 48
Table 30: Insulin Pens, Republic of Korea, Volume (Units) by Sub-Segment, Forecast, 2008-2015 49
Table 31: Insulin Delivery, Republic of Korea, Average Price ($), Historic, 2000-2008 50
Table 32: Insulin Delivery, Republic of Korea, Average Price ($), Forecast,, 2008-2015 50
Table 33: Insulin Delivery, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 51
Table 34: Insulin Delivery, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 52
Table 35: Novo Nordisk A/S Pipeline Products by Equipment Type 59
Table 36: Novo Nordisk A/S Pipeline Products By Development Stage 59
Table 37: Novo Nordisk A/S Pipeline Products By Therapy Area 59
Table 38: Novo Nordisk A/S Pipeline Products By Clinical Trials 59
Table 39: Medtronic, Inc. Pipeline Products by Equipment Type 63
Table 40: Medtronic, Inc. Pipeline Products By Development Stage 65
Table 41: Medtronic, Inc. Pipeline Products By Therapy Area 67
Table 42: Medtronic, Inc. Pipeline Products By Clinical Trials 69
Table 43: Medtronic, Inc. Pipeline Products By News Summary 70
Table 44: LifeScan, Inc. Pipeline Products by Equipment Type 71
Table 45: LifeScan, Inc. Pipeline Products By Development Stage 71
Table 46: LifeScan, Inc. Pipeline Products By Therapy Area 72
Table 47: LifeScan, Inc. Pipeline Products By Clinical Trials 72
Table 48: LifeScan, Inc. Pipeline Products By News Summary 72
Table 49: F. Hoffmann-La Roche Ltd Pipeline Products by Equipment Type 75
Table 50: F. Hoffmann-La Roche Ltd Pipeline Products By Development Stage 76
Table 51: F. Hoffmann-La Roche Ltd Pipeline Products By Therapy Area 76
Table 52: Eli Lilly and Company Pipeline Products by Equipment Type 79
Table 53: Eli Lilly and Company Pipeline Products By Development Stage 80
Table 54: Eli Lilly and Company Pipeline Products By Therapy Area 80
Table 55: Eli Lilly and Company Pipeline Products By Clinical Trials 80
Table 56: Eli Lilly and Company Pipeline Products By News Summary 80
Table 57: Bayer HealthCare AG Pipeline Products by Equipment Type 85
Table 58: Bayer HealthCare AG Pipeline Products By Development Stage 86
Table 59: Bayer HealthCare AG Pipeline Products By Therapy Area 86
Table 60: Bayer HealthCare AG Pipeline Products By News Summary 86
Table 61: ARKRAY, Inc. Pipeline Products by Equipment Type 87
Table 62: ARKRAY, Inc. Pipeline Products By Development Stage 87
Table 63: ARKRAY, Inc. Pipeline Products By Clinical Trials 87
Table 64: ARKRAY, Inc. Pipeline Products By News Summary 88
Table 65: Abbott Laboratories Pipeline Products by Equipment Type 92
Table 66: Abbott Laboratories Pipeline Products By Development Stage 92
Table 67: Abbott Laboratories Pipeline Products By Therapy Area 92
Table 68: USD to Local Currency, Average Exchange Rate 2008 98

Terumo Corporation
Smiths Medical
Sanofi-Aventis
Novo Nordisk A/S
Medtronic, Inc.
LifeScan, Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Becton, Dickinson and Company
Bayer HealthCare AG
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation
Abbott Laboratories
Shina Corporation

Customers who bought this item also bought

• Nanobiotechnology Applications, Markets and Companies
• Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings
• Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity
• Cell Therapy - Technologies, Markets and Companies
• Biosensors - A Global Market Overview
• Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth
• Global DNA & Gene Chip (Microarray) Market (2010 - 2015)
• Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017
• Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
• The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways